Hormones et Maladies Cardiovasculaires
Directeur : Pierre-Yves Scarabin

 

Hormones et Maladies Cardiovasculaires
Directeur : Pierre-Yves Scarabin

 

Hormones et Maladies Cardiovasculaires
Directeur : Pierre-Yves Scarabin

  1. Scarabin PY, Oger E, Plu-Bureau PY on behalf of the Estrogen and THromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
     
  2. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M.  Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women. A Randomised Controlled Trial. Arterioscl Thromb Vasc Biol 1997, 17: 3071-78.
     
  3. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, WahlD, Emmerich J and Scarabin PY on behalf of the EStrogen and THromboEmbolism Risk (ESTHER) Study Group.Hormone therapy and venous thromboembolism among postmenopausal women : impact of the route of estrogen administration and progestogens.  Circulation 2007; 115: 840-5.
     
  4. Canonico M, Plu-Bureau G, Lowe GD and Scarabin PY. Postmenopausal hormone therapy and risk ofvenous thromboembolism: a systematic review and meta-analysis. British Medical Journal 2008; 336: 1227-31.
     
  5. Straczek C, Oger E, Beau Yon de Jonage-Canonico M,  Plu-Bureau G, Conard, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, and Scarabin PY for the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy and venous thromboembolism among postmenopausal women : impact of the route of estrogen administration. Circulation 2005;112:3495-3500.

© Esther 2017